Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Br J Dermatol ; 186(3): 564-574, 2022 03.
Artigo em Inglês | MEDLINE | ID: mdl-34632574

RESUMO

BACKGROUND: A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome'). OBJECTIVES: To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome. METHODS: One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded. RESULTS: The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis. CONCLUSIONS: VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.


Assuntos
Gamopatia Monoclonal de Significância Indeterminada , Síndromes Mielodisplásicas , Humanos , Inflamação/genética , Mutação/genética , Síndromes Mielodisplásicas/diagnóstico , Enzimas Ativadoras de Ubiquitina
2.
J Hosp Infect ; 108: 15-18, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33197489

RESUMO

The performance of an in-house protocol for virus detection on commercialized electrostatic wipes (EWs) was assessed experimentally by impregnating them with suspensions of cytomegalovirus, adenovirus, and influenza virus, and by determining the recovery efficiency, repeatability, and detection limit of the protocol. The protocol was sensitive enough to detect 4 log10 gene copies of virus. At room temperature, influenza RNA was stable on EWs for at least four days. When EWs were placed high in 32 influenza-infected patients' rooms, influenza RNA was detectable in 75% (N = 24) of EWs, suggesting that EWs are simple and reliable methods for influenza virus airborne detection.


Assuntos
Microbiologia do Ar , Orthomyxoviridae/isolamento & purificação , Humanos , Influenza Humana/virologia , Limite de Detecção , Quartos de Pacientes , Reprodutibilidade dos Testes , Eletricidade Estática
4.
Rev Med Interne ; 40(3): 173-177, 2019 Mar.
Artigo em Francês | MEDLINE | ID: mdl-30501929

RESUMO

Since 1893, eosinopenia is a biological test to help a diagnosis of bacterial infection. Several publications have confirmed this hypothesis, particularly in the intensive care, pneumology and pediatric units. The value of this marker has been identified in vascular cerebral diseases and coronary bypass. Its contribution seems as relevant as procalcitonin, without extra cost. The diagnostic performance of this test was reinforced by a composite score (CIBLE score) that may improve its value in daily routine. Finally, monitoring eosinopenia appears to be a reliable mortality marker.


Assuntos
Agranulocitose/diagnóstico , Eosinófilos/patologia , Hematologia/tendências , Agranulocitose/etiologia , Agranulocitose/patologia , Infecções Bacterianas/sangue , Infecções Bacterianas/complicações , Infecções Bacterianas/diagnóstico , Hematologia/métodos , Humanos , Contagem de Leucócitos , Prognóstico
5.
Rev Med Interne ; 39(1): 10-16, 2018 Jan.
Artigo em Francês | MEDLINE | ID: mdl-29223347

RESUMO

INTRODUCTION: Several studies have shown that eosinopenia less than 0.04g/L is a marker of bacterial infection in the presence of unexplained inflammatory syndrome. The aim of our study was to test this hypothesis and to propose a predictive score for bacterial infection (score CIBLE, C reactive protein, bacterial infections, levels of leucocytes and eosinophils). PATIENTS AND METHODS: This was a single-center observational study of patients admitted to an internal medicine department in the year 2015 and presenting with an inflammatory biological syndrome. Patients were divided into 2 groups: bacterial infections (group 1) and nonbacterial inflammatory diseases (group 2). RESULTS: One hundred and ninety patients were included: 92 men (48.4 %) and 98 women (51.6 %). Mean age was 73.5±18.2 years [19-104]. Group 1 consisted of 124 patients (65.2 %) and group 2 of 66 patients (34.8 %). ROC analysis confirmed a cut-off level for eosinophils count at 0.04g/L as discriminant to predict bacterial infection. In a multivariate analysis, the eosinophil/neutrophil ratio, a history of COPD, the C reactive protein concentration, patient age and initial temperature were the most significant variables. They were used to build the CIBLE score. For a score higher than or equal to 87, the probability of a bacterial infection is at least 70 %. CONCLUSION: The CIBLE score appears to be a relevant and inexpensive tool to establish a probability for bacterial infection.


Assuntos
Infecções Bacterianas/diagnóstico , Biomarcadores/sangue , Eosinófilos/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Infecções Bacterianas/sangue , Feminino , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Projetos de Pesquisa , Adulto Jovem
6.
Rev Med Interne ; 38(7): 491-492, 2017 Jul.
Artigo em Francês | MEDLINE | ID: mdl-27055384
8.
Rev Med Interne ; 37(5): 307-20, 2016 May.
Artigo em Francês | MEDLINE | ID: mdl-26899776

RESUMO

PURPOSE: To develop French recommendations about the management of vaccinations, the screening of cervical cancer and the prevention of pneumocystis pneumonia in systemic lupus erythematosus (SLE). METHODS: Thirty-seven experts qualified in internal medicine, rheumatology, dermatology, nephrology and pediatrics have selected recommendations from a list of proposition based on available data from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified. RESULTS: Inactivated vaccines do not cause significant harm in SLE patients. Experts recommend that lupus patient should receive vaccinations accordingly to the recommendations and the schedules for the general public. Pneumococcal vaccination is recommended for all SLE patients. Influenza vaccination is recommended for immunosuppressed SLE patients. Live attenuated vaccines should be avoided in immunosuppressed patients. Yet, recent works suggest that they can be considered in mildly immunosuppressed patients. Experts have recommended a cervical cytology every year for immunosuppressed patients. No consensus was obtained for the prevention of pneumocystis pneumonia. CONCLUSION: These recommendations can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of SLE patients.


Assuntos
Prova Pericial , Controle de Infecções/normas , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/terapia , Guias de Prática Clínica como Assunto , Adolescente , Adulto , França , Humanos , Hospedeiro Imunocomprometido , Controle de Infecções/métodos , Infecções/diagnóstico , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/imunologia , Literatura de Revisão como Assunto , Vacinação/normas , Adulto Jovem
9.
Rev Med Interne ; 37(8): 529-35, 2016 Aug.
Artigo em Francês | MEDLINE | ID: mdl-26874812

RESUMO

Amyloidosis is mainly a systemic disease belonging to protein-folding diseases. The past 10 years have shown significant progress in typing and the clinical management of amyloidosis, in the identification of novel prognostic markers for risk-stratification, and also in the development of new therapeutic agents. Biological molecular techniques are now able to type amyloidosis which were unidentified. Cardiac MRI and biomarkers allow a precise risk-stratification, especially in AL amyloidosis. If necessary, this prognostic evaluation may lead to rapid changes in the chemotherapy treatment. Emerging treatments rely on biotherapies, gene therapy, immunotherapy and blocking analogous agents. They give hope about an increase of survival of patients with systemic amyloidosis.


Assuntos
Amiloidose/diagnóstico , Biomarcadores/análise , Amiloidose/terapia , Gerenciamento Clínico , Humanos , Prognóstico
10.
Lupus ; 24(11): 1161-8, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25862730

RESUMO

OBJECTIVES: Health-related quality of life (HRQoL) has not been fully explored in antiphospholipid syndrome (APS); therefore, we compared HRQoL between APS patients and the general population and assessed the impact of thromboembolic history. METHODS: HRQoL was measured in a multicentre cohort study by the Medical Outcomes Study Short-Form 36 (MOS-SF-36) questionnaire. HRQoL scores were compared to the French general population norms. Factors significantly associated with an impaired HRQoL were identified. RESULTS: A total of 115 patients with aPL and/or systemic lupus erythematosus (SLE) were included (mean age 42.7 ± 14.1 years old, 86 women). In 53 patients APS was diagnosed. Compared to general population norms, patients with APS had an impaired HRQoL. SLE-associated APS patients had the worst HRQoL scores (physical component summary (PCS)=40.8 ± 10.6; mental component summary (MCS)=40.6 ± 16.5) in comparison with SLE or aPL patients without thromboembolic history. In APS patients, history of arterial thrombosis significantly impaired HRQoL (PCS score: 42.2 ± 9.4 vs 49.2 ± 8.5; MCS score: 33.9 ± 13.7 vs 44.6 ± 10.3). CONCLUSION: Compared to the general population, APS patients experienced a lower HRQoL. In these patients, a history of arterial thrombosis significantly impaired HRQoL. Therefore, measurements of HRQoL should be included in APS patient management to assess the burden of the disease from a patient's perspective and to provide patients with the support they need.


Assuntos
Síndrome Antifosfolipídica/fisiopatologia , Adulto , Síndrome Antifosfolipídica/psicologia , Estudos de Coortes , Feminino , Nível de Saúde , Humanos , Lúpus Eritematoso Sistêmico/fisiopatologia , Lúpus Eritematoso Sistêmico/psicologia , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Qualidade de Vida , Fatores de Risco , Inquéritos e Questionários , Trombose/fisiopatologia
11.
Rev Med Interne ; 36(6): 372-80, 2015 Jun.
Artigo em Francês | MEDLINE | ID: mdl-25455954

RESUMO

PURPOSE: To develop French recommendations about screening and management of cardiovascular risk factors in systemic lupus erythematosus (SLE). METHODS: Thirty-nine experts qualified in internal medicine, rheumatology and nephrology have selected recommendations from a list developed based on evidence from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified. RESULTS: Experts recommended an annual screening of cardiovascular risk factors in SLE. Statins should be prescribed for primary prevention in SLE patients based on the level of LDL-cholesterol and the number of cardiovascular risk factors, considering SLE as an additional risk factor. For secondary prevention, experts have agreed on an LDL-cholesterol target of <0.7 g/L. Hypertension should be managed according to the 2013 European guidelines, using renin-angiotensin system blockers as first line agents in case of renal involvement. Aspirin can be prescribed in patients with high cardiovascular risk or with antiphospholipid antibodies. CONCLUSION: These recommendations about the screening and management of cardiovascular risk factors in SLE can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of SLE patients.


Assuntos
Doenças Cardiovasculares/etiologia , Lúpus Eritematoso Sistêmico/complicações , Programas de Rastreamento/métodos , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/tratamento farmacológico , Medicina Baseada em Evidências , Prova Pericial , Guias como Assunto , Humanos , Fatores de Risco , Prevenção Secundária
12.
Clin Exp Rheumatol ; 32(6 Suppl 86): S-145-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25151849

RESUMO

OBJECTIVES: High risk human papilloma-viruses (HR HPV) are associated with risk of cervical dysplasia and carcinoma. The risk is increased in patients with immune deficiency or auto-immune disease as systemic lupus erythematosus. Currently, no data are available about the human papillomavirus status in women with systemic sclerosis (SSc). METHODS: Thirty-one women with SSc were evaluated for cervical HPV infection and dysplasia, and compared to fifty age-matched control. Cervical swabs were tested by the INNO-LiPA assay®. Serum antibodies against HPV 16 and 18 were assessed using enzyme-linked immunosorbent assay in the SSc group. RESULTS: The overall HPV frequency was comparable between SSc and controls (32% vs. 38%), as well as the HR HPV frequency (28% vs. 34%), but infection by ≥2 HPV was two times more frequent in the SSc group (50% vs. 26% of the HPV positive samples). The most prevalent genotype was 52 in the SSc group (12%), and 52/53 in the control group (8% for both). Pap smears were within the normal range. Seropositivity for HPV 16 and 18 was 13% and 6.5%, respectively. A diffuse systemic sclerosis and a younger age at first intercourse were more frequent in cases of overall HPV positivity. Current smoking and a higher number of sexual partners were only observed in cases of seropositivity. CONCLUSIONS: This is the first study to evaluate HPV status in women with SSc. HR HPV52 was the most common genotype with a greater multi-HPV infection rate. This result needs to be confirmed in a larger study.


Assuntos
DNA Viral/genética , Infecções por Papillomavirus/epidemiologia , Escleroderma Sistêmico/epidemiologia , Neoplasias do Colo do Útero/epidemiologia , Idoso , Anticorpos Antivirais/imunologia , Estudos de Casos e Controles , Detecção Precoce de Câncer , Feminino , Genótipo , Papillomavirus Humano 16/imunologia , Papillomavirus Humano 18/imunologia , Humanos , Pessoa de Meia-Idade , Teste de Papanicolaou , Papillomaviridae/genética , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/imunologia , Fatores de Risco , Estudos Soroepidemiológicos , Parceiros Sexuais , Fumar/epidemiologia , Neoplasias do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/imunologia , Esfregaço Vaginal
13.
Rev Med Interne ; 35(12): 790-3, 2014 Dec.
Artigo em Francês | MEDLINE | ID: mdl-24834803

RESUMO

PURPOSE: Uveitis is a disorder for which etiologic assessment procedures are still not codified. Clinical presentation is heterogenous, with poor correlation between symptoms and neurological involvement. The aim of our study was to assess the contribution of cerebral magnetic resonance imaging (MRI) in the management of uveitis. METHODS: Seventy-one patients, 26 men and 45 women, were included between January 1st, 2000 and March 31st, 2008, in two groups "contributory MRI" and "not contributory MRI" according to diagnostic contribution of MRI. Clinical characteristics of uveitis, inflammatory, immunological and infectious biological features, and cerebral MRI were analyzed. RESULTS: A diagnostics was established in 38 (53.5%) patients. Five patients with multiple sclerosis and one case of Behçet's disease were diagnosed using cerebral MRI. CONCLUSION: This study points out cerebral MRI contribution as a second-line examination for the etiological diagnosis of uveitis especially in case of suspicion of multiple sclerosis or Behçet's disease.


Assuntos
Encéfalo/patologia , Imageamento por Ressonância Magnética , Uveíte/etiologia , Adulto , Síndrome de Behçet/diagnóstico , Feminino , Humanos , Masculino , Esclerose Múltipla/diagnóstico , Estudos Retrospectivos
14.
Rev Med Interne ; 35(4): 231-4, 2014 Apr.
Artigo em Francês | MEDLINE | ID: mdl-23849903

RESUMO

INTRODUCTION: The objective of this study was to assess the application of local and national recommendations in the management of community-acquired pneumonia in an internal medicine department with an antibiotic referent physician and in an emergency department. PATIENTS AND METHODS: This was a retrospective single-center study including patients admitted with community-acquired pneumonia in the internal medicine department of the University Hospital of Besançon after an initial admission in the emergency department. RESULTS: One hundred patients (58 women and 42 men) were included. The mean age was 79 ± 11 years. The prescriptions done in the emergency department were in accordance with local recommendations or Société de pathologie infectieuse de langue française (SPILF) recommendations in 62% of cases. The prescriptions followed the recommendations in 94% of cases in internal medicine department (P<0.05). The lack of initial antibiotic treatment had no influence on morbidity and mortality. CONCLUSION: The guidelines for infectious diseases treatment were significantly more often applied in a department where a referent physician was designated for this.


Assuntos
Infecções Comunitárias Adquiridas/terapia , Fidelidade a Diretrizes/estatística & dados numéricos , Pneumonia/terapia , Infecções Respiratórias/terapia , Idoso , Idoso de 80 Anos ou mais , Infecções Comunitárias Adquiridas/epidemiologia , Serviço Hospitalar de Emergência , Feminino , França/epidemiologia , Departamentos Hospitalares , Hospitais Universitários , Humanos , Medicina Interna , Masculino , Pneumonia/epidemiologia , Guias de Prática Clínica como Assunto , Infecções Respiratórias/epidemiologia , Estudos Retrospectivos
15.
Rev Med Interne ; 35(6): 353-6, 2014 Jun.
Artigo em Francês | MEDLINE | ID: mdl-23968563

RESUMO

PURPOSE: To date only a few studies regarding pulmonary embolism (PE) in elderly have been published. The aim of this study was to determine the clinical features of PE in elderly patients (≥ 75 years). METHODS: All patients hospitalized for PE in our internal medicine department from January 2005 to December 2010 were included in the study. The aim was to compare the features of PE in elderly patients (≥ 75 years) to those of patients younger than 75 years. The following data were recorded: past medical history, risk factors for venous thrombo-embolism (VTE), clinical features, and PE etiologies. RESULTS: The population was composed of 64 patients (women 56%) with a median age of 82 years (IQR: 13.5). There was no statistical difference for risk factors of VTE. Syncope was more frequent in elderly patients (33% versus 7%, P=0.04) whereas thoracic pain predominated in younger patients (36,5% versus 7%, P=0.005). Chronic obstructive pulmonary disease was more frequent in the past medical history of elderly patients. The diagnostic of PE was less suspected in elderly patients (47% versus 72%, P=0.035). The etiologies were similar between the two groups. CONCLUSION: Our study highlights the frequency of syncope as the presenting feature of PE in elderly, whereas thoracic pain is uncommon. We confirmed the difficulty to diagnose PE in elderly population.


Assuntos
Embolia Pulmonar/diagnóstico , Embolia Pulmonar/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Dor no Peito/epidemiologia , Dispneia/epidemiologia , Feminino , França/epidemiologia , Hospitalização , Humanos , Imobilização/efeitos adversos , Masculino , Neoplasias/epidemiologia , Complicações Pós-Operatórias/epidemiologia , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Estudos Retrospectivos , Fatores de Risco , Síncope/epidemiologia , Trombose Venosa/epidemiologia
16.
Rev Med Interne ; 33(3): e14-6, 2012 Mar.
Artigo em Francês | MEDLINE | ID: mdl-21429634

RESUMO

Acquired ichthyosis and livedoid palmoplantar keratoderma have rarely been described in systemic lupus erythematosus (SLE). In the first case, a 51-year-old man presented with generalized acquired ichthyosis associated with renal glomurelosclerosis and neurolupus. rituximab allowed total resolution of the acquired ichthyosis. A livedoid palmoplantar keratoderma was observed in a 45-year-old woman as the initial clinical manifestation of a systemic lupus erythematosus associated with Raynaud's phenomenon, photosensitivity and inflammatory polyarthralgia. Although the pathophysiology is not well-defined, these unusual cutaneous manifestations should be considered by physicians when diagnosis of SLE is suspected.


Assuntos
Ictiose/diagnóstico , Ceratodermia Palmar e Plantar/diagnóstico , Lúpus Eritematoso Sistêmico/diagnóstico , Diagnóstico Diferencial , Feminino , Humanos , Ictiose/etiologia , Ceratodermia Palmar e Plantar/etiologia , Lúpus Eritematoso Sistêmico/complicações , Masculino , Pessoa de Meia-Idade , Dermatopatias/diagnóstico
17.
Rev Med Interne ; 31(11): e7-8, 2010 Nov.
Artigo em Francês | MEDLINE | ID: mdl-20554093

RESUMO

Central neurological involvement in Behcet's disease (neuro-Behcet) occurs in 10 to 20% out of the patient. We report a 47-year-old man treated with cyclosporine who presented with neurologic manifestations of Behçet's disease. Relationship between cyclosporine and neuro-Behcet's disease are discussed.


Assuntos
Síndrome de Behçet/induzido quimicamente , Ciclosporina/efeitos adversos , Argélia , Síndrome de Behçet/genética , Humanos , Incidência , Masculino , Pessoa de Meia-Idade
19.
Rev Med Interne ; 31(6): 403-5, 2010 Jun.
Artigo em Francês | MEDLINE | ID: mdl-20430488

RESUMO

PURPOSE: Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed. METHODS: Single-centre non-randomized retrospective open study. RESULTS: Forty-seven patients were treated with thalidomide for recurrent aphthosis (41 patients) or Behçet disease (six patients). Remission was obtained with a dose of 25 mg daily. Discontinuation of treatment for side effects was not observed in this case series. CONCLUSION: Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of aphthosis.


Assuntos
Imunossupressores/uso terapêutico , Estomatite Aftosa/tratamento farmacológico , Talidomida/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Síndrome de Behçet/tratamento farmacológico , Feminino , Humanos , Imunossupressores/efeitos adversos , Masculino , Pessoa de Meia-Idade , Recidiva , Indução de Remissão , Estudos Retrospectivos , Estomatite Aftosa/diagnóstico , Talidomida/efeitos adversos , Resultado do Tratamento
20.
Rev Med Interne ; 31(6): 406-10, 2010 Jun.
Artigo em Francês | MEDLINE | ID: mdl-20398978

RESUMO

PURPOSE: There is a lack for French official guidelines for prophylaxis of venous thromboembolism. Therefore an internal referential based on MEDENOX study inclusion criteria was proposed in our internal medicine department. The main goal of this study was to assess the appropriateness of thromboprophylaxis prescriptions regarding the internal referential. METHODS: A retrospective and observational study included all the patients older than 18 years hospitalized in February and July 2007 in our internal medicine department for at least 48 hours and receiving no anticoagulant treatment. For each patient the following criteria were recorded: admission diagnosis, past medical history, current treatment, creatinine clearance, duration of hospitalisation, thromboprophylactic treatment and course during hospital stay. RESULTS: Eighty-nine patients were included. Forty-two (47.2%) patients had a thromboprophylaxis indication. Among them 40 (95.2%) actually received a thromboprophylaxis. Ten of the 47 patients (21.2%) without thromboprophylaxis indication also received a thromboprophylaxis. The most frequent indications for thromboprophylaxis were an infectious disease with an age greater than 75 years old and a cardiac failure stage III or IV of the NYHA. CONCLUSION: Most of the studies concerning medical thromboprophylaxis highlight its underutilization in the absence of a referential. In our study the referential use increased the percentage of patients with appropriate thromboprophylaxis but was associated with over-prescriptions in 21.2% of the cases. The use of electronic alerts may increase the number of patients receiving the appropriate treatment.


Assuntos
Anticoagulantes/uso terapêutico , Departamentos Hospitalares , Hospitalização , Medicina Interna , Tromboembolia Venosa/prevenção & controle , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças Transmissíveis/complicações , Doenças Transmissíveis/tratamento farmacológico , Feminino , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Guias de Prática Clínica como Assunto , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA